Skip to content
10-Q

Quarterly Report

ANI PHARMACEUTICALS INC ANIP

0001023024-26-000050

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 21.54M sh
Shares Diluted Q1 2026 · Mar 31, 2025 20.05M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $19.76M
Stock Repurchased Q1 2026 · Mar 31, 2025 $10M
Dividends Paid Q1 2026 · Mar 31, 2026 $0
Dividends Paid Q1 2026 · Mar 31, 2025 $406K
Capex Q1 2026 · Mar 31, 2026 $6.07M
Capex Q1 2026 · Mar 31, 2025 $2.47M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $58.38M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $34.99M
Long Term Debt Q1 2026 · Mar 31, 2026 $286M
Long Term Debt Q1 2026 · Dec 31, 2025 $291.84M
Short Term Debt Q1 2026 · Mar 31, 2026 $19.3M
Short Term Debt Q1 2026 · Dec 31, 2025 $17.27M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $311.18M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $285.59M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $149.8M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $144.86M
Stockholders Equity Q1 2026 · Mar 31, 2026 $562.3M
Stockholders Equity Q1 2026 · Dec 31, 2025 $540.72M
Current Liabilities Q1 2026 · Mar 31, 2026 $239.51M
Current Liabilities Q1 2026 · Dec 31, 2025 $278.11M
Total Liabilities Q1 2026 · Mar 31, 2026 $859.67M
Total Liabilities Q1 2026 · Dec 31, 2025 $899.65M
Current Assets Q1 2026 · Mar 31, 2026 $747.08M
Current Assets Q1 2026 · Dec 31, 2025 $753.12M
Total Assets Q1 2026 · Mar 31, 2026 $1.42B
Total Assets Q1 2026 · Dec 31, 2025 $1.44B
Eps Diluted Q1 2026 · Mar 31, 2026 $1.28
Eps Diluted Q1 2026 · Mar 31, 2025 $0.69
Eps Basic Q1 2026 · Mar 31, 2026 $1.31
Eps Basic Q1 2026 · Mar 31, 2025 $0.70
Sga Expense Q1 2026 · Mar 31, 2026 $73.66M
Sga Expense Q1 2026 · Mar 31, 2025 $76.53M
Rd Expense Q1 2026 · Mar 31, 2026 $10.6M
Rd Expense Q1 2026 · Mar 31, 2025 $10.56M
Net Income Q1 2026 · Mar 31, 2026 $29.49M
Net Income Q1 2026 · Mar 31, 2025 $15.68M
Operating Income Q1 2026 · Mar 31, 2026 $38.89M
Operating Income Q1 2026 · Mar 31, 2025 $26.19M
Revenue Q1 2026 · Mar 31, 2026 $237.46M
Revenue Q1 2026 · Mar 31, 2025 $197.12M